Aratana Theraptcs Cm (PETX) 7.50 $PETX
Aratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic
PR Newswire - Thu Jun 02, 8:23AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company received a technical section complete letter for chemistry, manufacturing and controls (CMC) for NOCITA® (bupivacaine liposome injectable suspension) from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). Nocita is being investigated as a therapeutic option to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and works as a long-acting local anesthetic designed to provide up to 72 hours of post-operative pain control.
PETX: 7.50 (-0.09)
Aratana Therapeutics to Participate at Two Upcoming Investor Conferences
PR Newswire - Mon May 23, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
PETX: 7.50 (-0.09)
Aratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution)
PR Newswire - Tue May 17, 4:46PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017.
PETX: 7.50 (-0.09)
Aratana reports 1Q loss
Automated Insights - Thu May 05, 5:38PM CDT
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $18.1 million in its first quarter.
PETX: 7.50 (-0.09)
Aratana Therapeutics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Aratana Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Mon May 02, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
PETX: 7.50 (-0.09)
Aratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health
PR Newswire - Mon Apr 25, 3:10PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals will host a conference call today, Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) that was announced this afternoon.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Aratana, Elanco Announce Global Strategic Collaboration
PR Newswire - Mon Apr 25, 3:05PM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 6.07 (+0.18), EBIO: 3.80 (-0.17), PTCT: 6.10 (+0.13), PETX: 7.50 (-0.09), ARRY: 4.22 (+0.48)
Aratana Therapeutics to Report First Quarter 2016 Financial Results
PR Newswire - Thu Apr 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
PETX: 7.50 (-0.09)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.89 (unch), VVUS: 1.05 (-0.02), PETX: 7.50 (-0.09), GALE: 0.45 (+0.01)
Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
PR Newswire - Thu Mar 31, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016 from 7:00 - 7:50 a.m. Lesley Rausch-Derra, DVM, MS, Vice President of Regulatory Affairs and Drug Development at Aratana Therapeutics, will present the pivotal data during the Sunrise Session for registered conference attendees. Presentation slides are also available in the Aratana Investor Room.
PETX: 7.50 (-0.09)
Zacks.com featured expert Kevin Matras highlights: Aratana Therapeutics, AK Steel Holding, Ariad Pharmaceuticals, Lake Shore Gold and Pretium Resources
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Zacks.com featured expert Kevin Matras highlights: Aratana Therapeutics, AK Steel Holding, Ariad Pharmaceuticals, Lake Shore Gold and Pretium Resources
LSG: 1.47 (+0.01), PETX: 7.50 (-0.09), AKS: 6.25 (-0.31), ARIA: 9.71 (+0.20), PVG: 11.99 (+0.11)
Aratana Therapeutics Files for Second FDA Approval
PR Newswire - Tue Mar 22, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company submitted an administrative New Animal Drug Application (NADA) for ENTYCE® (capromorelin oral solution) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) for appetite stimulation for dogs. The Animal Drug User Fee Act (ADUFA) date is May 21, 2016. Aratana anticipates Entyce will be commercially available to veterinarians in late-2016 or shortly thereafter.
PETX: 7.50 (-0.09)
Aratana Therapeutics Granted First FDA Approval
PR Newswire - Mon Mar 21, 1:56PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Food and Drug Administration's Center for Veterinary Medicine (CVM) approved GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is expected to be available to veterinarians in fall 2016.
PETX: 7.50 (-0.09)
Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its fourth quarter 2015 and full year 2015 financial results. For the quarter ended December 31, 2015, Aratana reported a net loss of $12.9 million or $0.37 basic loss per share and for the full year of 2015, Aratana reported a net loss of $84.1 million or $2.45 basic loss per share.
PETX: 7.50 (-0.09)
New Strong Buy Stocks for March 10th
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
AGII: 51.71 (-0.18), VLRS: 18.34 (+0.24), PETX: 7.50 (-0.09), BKS: 12.98 (-0.10), ALEX: 40.11 (+0.71)
Nivalis (NVLS) Provides Update on Cystic Fibrosis Candidate
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:00PM CST
Nivalis Therapeutics (NVLS) announced the expansion of the clinical development plan for N91115 for the treatment of patients with cystic fibrosis.
VRTX: 98.20 (+1.20), NVLS: 4.76 (+0.08), PETX: 7.50 (-0.09), TRIL: 9.49 (+0.90)
Aratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic
PR Newswire - Thu Jun 02, 8:23AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company received a technical section complete letter for chemistry, manufacturing and controls (CMC) for NOCITA® (bupivacaine liposome injectable suspension) from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM). Nocita is being investigated as a therapeutic option to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and works as a long-acting local anesthetic designed to provide up to 72 hours of post-operative pain control.
PETX: 7.50 (-0.09)
Aratana Therapeutics to Participate at Two Upcoming Investor Conferences
PR Newswire - Mon May 23, 7:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, plans to present at Stifel Dental & Veterinary Conference on Wednesday, June 1 at 10:55 a.m. ET in New York City and at Jefferies Healthcare Conference on Tuesday, June 7 at 2:30 p.m. ET in New York City.
PETX: 7.50 (-0.09)
Aratana Therapeutics Granted FDA Approval of ENTYCE® (capromorelin oral solution)
PR Newswire - Tue May 17, 4:46PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved Entyce for appetite stimulation in dogs. Aratana intends to commercially launch Entyce in conjunction with the North American Veterinary Conference in February 2017.
PETX: 7.50 (-0.09)
Aratana reports 1Q loss
Automated Insights - Thu May 05, 5:38PM CDT
LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $18.1 million in its first quarter.
PETX: 7.50 (-0.09)
Aratana Therapeutics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Aratana Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference
PR Newswire - Mon May 02, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 10, 2016 at 5:00 p.m. PT.
PETX: 7.50 (-0.09)
Aratana Therapeutics to Discuss Global Strategic Collaboration with Elanco Animal Health
PR Newswire - Mon Apr 25, 3:10PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals will host a conference call today, Monday, April 25, 2016, at 6:00 p.m. ET to update the investment community regarding the strategic collaboration with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) that was announced this afternoon.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Aratana, Elanco Announce Global Strategic Collaboration
PR Newswire - Mon Apr 25, 3:05PM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana's Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.
PETX: 7.50 (-0.09), LLY: 83.18 (+0.29)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 6.07 (+0.18), EBIO: 3.80 (-0.17), PTCT: 6.10 (+0.13), PETX: 7.50 (-0.09), ARRY: 4.22 (+0.48)
Aratana Therapeutics to Report First Quarter 2016 Financial Results
PR Newswire - Thu Apr 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, May 6, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ending March 31, 2016.
PETX: 7.50 (-0.09)
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.89 (unch), VVUS: 1.05 (-0.02), PETX: 7.50 (-0.09), GALE: 0.45 (+0.01)
Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
PR Newswire - Thu Mar 31, 8:00AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016 from 7:00 - 7:50 a.m. Lesley Rausch-Derra, DVM, MS, Vice President of Regulatory Affairs and Drug Development at Aratana Therapeutics, will present the pivotal data during the Sunrise Session for registered conference attendees. Presentation slides are also available in the Aratana Investor Room.
PETX: 7.50 (-0.09)
Zacks.com featured expert Kevin Matras highlights: Aratana Therapeutics, AK Steel Holding, Ariad Pharmaceuticals, Lake Shore Gold and Pretium Resources
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Zacks.com featured expert Kevin Matras highlights: Aratana Therapeutics, AK Steel Holding, Ariad Pharmaceuticals, Lake Shore Gold and Pretium Resources
LSG: 1.47 (+0.01), PETX: 7.50 (-0.09), AKS: 6.25 (-0.31), ARIA: 9.71 (+0.20), PVG: 11.99 (+0.11)
Aratana Therapeutics Files for Second FDA Approval
PR Newswire - Tue Mar 22, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company submitted an administrative New Animal Drug Application (NADA) for ENTYCE® (capromorelin oral solution) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) for appetite stimulation for dogs. The Animal Drug User Fee Act (ADUFA) date is May 21, 2016. Aratana anticipates Entyce will be commercially available to veterinarians in late-2016 or shortly thereafter.
PETX: 7.50 (-0.09)
Aratana Therapeutics Granted First FDA Approval
PR Newswire - Mon Mar 21, 1:56PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Food and Drug Administration's Center for Veterinary Medicine (CVM) approved GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is expected to be available to veterinarians in fall 2016.
PETX: 7.50 (-0.09)
Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 14, 3:05PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its fourth quarter 2015 and full year 2015 financial results. For the quarter ended December 31, 2015, Aratana reported a net loss of $12.9 million or $0.37 basic loss per share and for the full year of 2015, Aratana reported a net loss of $84.1 million or $2.45 basic loss per share.
PETX: 7.50 (-0.09)
New Strong Buy Stocks for March 10th
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
AGII: 51.71 (-0.18), VLRS: 18.34 (+0.24), PETX: 7.50 (-0.09), BKS: 12.98 (-0.10), ALEX: 40.11 (+0.71)
Nivalis (NVLS) Provides Update on Cystic Fibrosis Candidate
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:00PM CST
Nivalis Therapeutics (NVLS) announced the expansion of the clinical development plan for N91115 for the treatment of patients with cystic fibrosis.
VRTX: 98.20 (+1.20), NVLS: 4.76 (+0.08), PETX: 7.50 (-0.09), TRIL: 9.49 (+0.90)
